Clinical Trial Update: 3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals

View source ↗

Summary

A terminated clinical trial update presenting a 3-year observational virology follow-up in participants from Idenix anti-HCV direct-acting antiviral studies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Idenix anti-HCV direct-acting antivirals

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Status: TERMINATED